L’actualité de Novigenix
Suivez toute l’actualité de Novigenix
Novigenix and IMMUcan forge a transformative partnership in AI-driven immunotherapy advancements
04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients. IMMUcan consortium aims to advance cancer
Revolutionizing drug development: Novigenix unveils AI-powered RNA analysis for immune response profiling
Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as unique as the person it
Novigenix appoints Dr. Pedro Romero as Chief Medical & Scientific Officer
LAUSANNE, SWITZERLAND – Novigenix, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix. In his new role as Chief
Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for whole-blood RNA biomarkers, and mapping of
Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society for Medical Oncology (ESMO) GI
Novigenix Appoints Dr. Pedro Romero as Director of Medical & Scientific Affairs
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune oncology expertise to the team.
L’actualité du web
Retrouvez des informations importantes relatives au cancer du côlon
Le dépistage du cancer colorectal devrait aller de soi à partir de 50ans
PRÉVENTION Le dépistage du cancer colorectal est volontaire - mais les médecins le recommandent fortement. Prof. Dr. med. Christoph Beglinger Specialist for Gastroenterology u. Internal Medicine Cancer Colorectal - Dépistage : il y a maintenant trois options pour la prévention. La Suisse est à la traîne dans le dépistage du cancer colorectal selon une comparaison internationale. Seuls 30% de la population de plus
Le Cancer du côlon peut-il être évité ?
Même si il n'y a aucun moyen sûr pour éviter le cancer du côlon, certains facteurs pourraient permettre de le prévenir et ainsi réduire le risque d'en développer un. Le dépistage fait partie des facteurs que vous contrôlez et qui vous aidera à réduire votre risque de développer un cancer colorectal. Plus il est dépisté tôt, mieux il se soigne. Le
Les symptômes associés au cancer colorectal
Le cancer du côlon évolue lentement et ne présente souvent pas de signes ou symptômes avant d’être à un stade plus avancé1. C'est pourquoi il est bien trop souvent détecté tardivement alors qu'une détection précoce augmente les chances de survie. Même si il ne faut pas attendre l'apparation des premiers symptômes pour se faire dépister, il est important de reconnaitre les